Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425003 · ClinicalTrials.gov registry record · Phase 1
Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration
A Phase 1 study, sponsored by Calico Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT06425003: Completed Phase 1 study, sponsored by Calico Life Sciences.
NCT06425003 is a Phase 1 study that has completed, run by Calico Life Sciences. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06425003, a Phase 1 study, has completed, sponsored by Calico Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-CLS-7262 in healthy, male volunteers following administration of a single oral dose.
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Interventions
- DRUG [14C] ABBV-CLS-7262
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2024-07-12 |
| Phase | Phase 1 |
What the finished NCT06425003 record still lists
NCT06425003 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C] ABBV-CLS-7262 is the first listed.
NCT06425003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06425003 about?
NCT06425003 is a clinical study titled "Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration". The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of \[14C\] ABBV-CLS-7262 in healthy, male volunteers following administration of a single oral dose.
What is the current status of trial NCT06425003?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2024-05-21. Estimated completion is 2024-07-12.
What interventions are being tested in trial NCT06425003?
The interventions under investigation include: [14C] ABBV-CLS-7262 (DRUG).
Who is sponsoring clinical trial NCT06425003?
This trial is sponsored by Calico Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06425003's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI